UK pharma industry signs landmark deal with government health service over drug prices
England’s National Health Service and the pharma industry on Monday morning announced a new five-year deal that will save the NHS £14 billion ($17.4 billion) in drug costs, but also double the annual allowed growth of branded medicines between 2024 and 2027.
The agreement, which runs from 2024 through the end of 2028, sets a yearly cap on the total allowed sales value of branded medicines to the NHS each year. Sales above the cap are paid back to the government via a levy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.